Press Release

Kirkland Represents SciClone Pharmaceuticals on Voluntary Share Buy-Back Offer

Kirkland & Ellis advised SciClone Pharmaceuticals (Holdings) Limited (HKSE: 6600), a biopharmaceutical company with an integrated platform for product development and commercialization, on its HK$780 million voluntary conditional cash offer to buy-back up to 77,534,791 shares at HK$10.06 per share, representing approximately 11.16% of SciClone Pharmaceuticals’ total issued share capital. The offer is subject to, among other things, approvals by the independent shareholders of SciClone Pharmaceuticals. 

Read SciClone Pharmaceuticals’ announcement

The Kirkland team was led by transactional partner Joey Chau.